Clinical Trial Detail

NCT ID NCT03236935
Title Phase Ib of L-NMMA and Pembrolizumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Jorge G. Darcourt
Indications

transitional cell carcinoma

head and neck squamous cell carcinoma

lung non-small cell carcinoma

melanoma

Hodgkin's lymphoma

Advanced Solid Tumor

Therapies

L-NMMA + Pembrolizumab

Age Groups: senior adult

Additional content available in CKB BOOST